Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice.
Intramuscular injection of DNA vaccines elicits potent humoral and cellular immune responses in mice. However, DNA vaccines are less efficient in larger animal models and humans. To gain a better understanding of the factors limiting the efficacy of DNA vaccines, we used fluorescence-labeled plasmid DNA in mice to 1) define the macroscopic and microscopic distribution of DNA after injection into the tibialis anterior muscle, 2) characterize cellular uptake and expression of DNA in muscle and draining lymph nodes, and 3) determine the effect of modifying DNA distribution and cellular uptake by volume changes or electroporation on the magnitude of the immune response. Injection of a standard 50-microl dose resulted in the rapid dispersion of labeled DNA throughout the muscle. DNA was internalized within 5 min by muscle cells near the injection site and over several hours by cells that were located along muscle fibers and in the draining lymph nodes. Histochemical staining and analysis of mRNA expression in isolated cells by RT-PCR showed that the transgene was detectably expressed only by muscle cells, despite substantial DNA uptake by non-muscle cells. Reduction of the injection volume to 5 microl resulted in substantially less uptake and expression of DNA by muscle cells, and correspondingly lower immune responses against the transgene product. However, expression and immunogenicity were restored when the 5-microl injection was followed by electroporation in vivo. These findings indicate that distribution and cellular uptake significantly affect the immunogenicity of DNA vaccines.
Dupuis
M
M
Cardiovascular Research Institute and Department of Anatomy, University of California, San Francisco, CA 94143, USA.
Denis-Mize
K
K
Woo
C
C
Goldbeck
C
C
Selby
M J
MJ
Chen
M
M
Otten
G R
GR
Ulmer
J B
JB
Donnelly
J J
JJ
Ott
G
G
McDonald
D M
DM
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology / Q000493:pharmacokinetics; D000818:Animals; D000956:Antigens, Viral / Q000008:administration & dosage / Q000276:immunology; D004279:DNA, Viral / Q000378:metabolism; D018274:Electroporation; D005786:Gene Expression Regulation; D015683:Gene Products, gag / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D015483:HIV Antibodies / Q000096:biosynthesis / Q000097:blood; D007273:Injections, Intramuscular; D008156:Luciferases / Q000235:genetics / Q000378:metabolism; D008198:Lymph Nodes / Q000166:cytology / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008822:Mice, Transgenic; D018482:Muscle, Skeletal / Q000166:cytology / Q000201:enzymology / Q000378:metabolism; D010957:Plasmids / Q000008:administration & dosage / Q000276:immunology; D019076:Transgenes / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology* / Q000493:pharmacokinetics*
D016915:AIDS Vaccines; D000956:Antigens, Viral; D004279:DNA, Viral; D015683:Gene Products, gag; D015483:HIV Antibodies; D019444:Vaccines, DNA; D008156:Luciferases